Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia

Eur J Haematol. 2005 Apr;74(4):277-81. doi: 10.1111/j.1600-0609.2004.00383.x.

Abstract

Fludarabine-based cycles severely impair mobilisation and collection of peripheral blood stem cells (PBSC) in acute myeloid leukaemia (AML). In an effort of reversing this side-effect, we studied the action on mobilisation and collection of PBSC of a low-dose regimen: 5-d Mini-ICE (oral idarubicin and etoposide; subcutaneous cytosine arabinoside) administered after fludarabine-based regimens in seven adult AML patients. Leukapheresis were started when the CD34+ cell count was more than 10/microL. The median number of harvested CD34+ cells was 8.1 x 10(6)/kg (range 3.08-15.2). All the patients were successfully submitted to PBSC transplantation. Median times to neutrophil and platelet recovery were rapid with a normal transfusional support. We suggest that the Mini-ICE programme is feasible, well tolerated and effective in terms of PBSC mobilisation and collection in low-yield AML patients previously treated with fludarabine. It is well known that a negative effect on stem cell mobilisation and harvest is observed not only after fludarabine administration in AML or low-grade lymphomas, but also after cycles based on different agents, such as thalidomide in multiple myeloma. This preliminary experience, if confirmed on larger series and/or other haematological malignancies, could open new opportunities to perform autologous PBSC transplantation in heavily pretreated cases, allowing a full source of therapeutic options before the start of the mobilisation process.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cytarabine / administration & dosage*
  • Etoposide / administration & dosage*
  • Female
  • Hematopoietic Stem Cell Mobilization / methods*
  • Humans
  • Idarubicin / administration & dosage*
  • Leukapheresis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation
  • Transplantation, Autologous
  • Vidarabine / administration & dosage*
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives*

Substances

  • Cytarabine
  • Etoposide
  • Vidarabine
  • fludarabine
  • Idarubicin

Supplementary concepts

  • ICE protocol 4